Open AccessImmunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide
Author(s) -
Samar Galal Younis,
Rasha Khedr,
Safinaz H. El-Shorbagy
Publication year - 2016
Publication title -
journal of egyptian national cancer institute/journal of the egyptian national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.398
H-Index - 22
eISSN - 2589-0409
pISSN - 1110-0362
DOI - 10.1016/j.jnci.2015.11.003
Subject(s) - temozolomide , medicine , concomitant , oncology , radiation therapy , immunohistochemistry , methyltransferase , chemotherapy , adjuvant , adjuvant therapy , predictive marker , pathology , cancer , biochemistry , chemistry , methylation , gene
O6-methylguanine-DNA methyltransferase (MGMT) protein expression using immunohistochemical analysis was proposed as a prognostic marker for patients with newly diagnosed glioblastoma (GBM) treated with radiation therapy with concurrent and adjuvant Temozolomide (TMZ).